drugset / Trial / NCT02662855
Efficacy of Favipiravir Against Severe Ebola Virus Disease
Phase 2
Completed
77 enrolled
Beijing Institute of Pharmacology and Toxicology
307 Hospital of PLA · collabBeijing 302 Hospital · collabCenters for Disease Control and Prevention, China · collabSierra Leone-China Friendship Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to explore the therapeutic efficacy of Favipiravir, a broad-spectrum antiviral drug against severe cases of Ebola Virus Disease (EVD), which is the most difficult aspect for clinical management of EVD due to its high fatality rate.
Timeline
- Start
- 2014-11
- Primary completion
- 2015-04
- Completion
- 2015-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Favipiravir | Small molecule | 600 mg | Oral |